-
Relypsa Up 10% Following Encouraging Phase 1 Study Results
Tuesday, January 26, 2016 - 9:30am | 262Shares of Relypsa Inc (NASDAQ: RLYP), a biopharmaceutical company that focuses on non-absorbed polymeric drugs to tread disorders in the areas of renal, cardiovascular and metabolic diseases, were trading higher by more than 10 percent early Tuesday morning. Relypsa announced after Monday's close...